Skip to Content Skip to Content

Bioengineering

Penn third-year named 2024 Udall Scholar
Joey Wu standing outside wearing a suit and tie

Third-year undergraduate Joey Wu has been named a 2024 Udall Scholar.

(Image: Courtesy of the Center for Undergraduate Research and Fellowships)

Penn third-year named 2024 Udall Scholar

Third-year Joey Wu, studying bioengineering and environmental science in the Vagelos Integrated Program in Energy Research (VIPER) program, has been named a 2024 Udall Scholar.
A novel technique to form human artificial chromosomes
Microscopic view of DNA.

Image: iStock/Mohammed Haneefa Nizamudeen

A novel technique to form human artificial chromosomes

Penn researchers say the new technique for making human artificial chromosomes from single, long constructs of designer DNA will allow for more efficient laboratory research.

Alex Gardner

Sherry Gao pushes the boundaries of genetic engineering
Sherry Gao.

Sherry (Xue) Gao, Presidental Penn Compact Associate Professor in Bioengineering.

(Image: Courtesy of Penn Engineering Today)

Sherry Gao pushes the boundaries of genetic engineering

The Presidential Penn Compact Associate Professor in Chemical and Biomolecular Engineering aims to make gene editing tools like CRISPR more accurate, and encourage first generation students along the way.

From Penn Engineering Today

New molecules, inspired by space shuttles, advance lipid nanoparticle delivery for weight control
Microscopic view of lipid nanoparticles.

Like space shuttles using booster rockets to breach the atmosphere, lipid nanoparticles equipped with the new molecule more successfully deliver medicinal payloads.

(Image: Courtesy of Penn Engineering)

New molecules, inspired by space shuttles, advance lipid nanoparticle delivery for weight control

Penn Engineering researchers have invented a new way to synthesize the key chemical components of lipid nanoparticles that help protect and deliver medicinal payloads.

From Penn Engineering Today

‘Switchable’ bispecific antibodies pave way for safer cancer treatment
Artist's depiction of tumor microenvironment

Bispecific T cell engagers are emerging as a powerful class of immunotherapy to treat cancer but are sometimes hindered by unwanted outcomes, such as on-target, off-tumor toxicity; cytokine release syndrome; and neurotoxicity. Now, researchers Penn researchers have developed a novel “switchable” bispecific T cell engager that mitigates these negative effects by co-opting a drug already approved by the FDA.

(Image: iStock / CIPhotos)

‘Switchable’ bispecific antibodies pave way for safer cancer treatment

Immunotherapy utilizing an FDA-approved drug has enabled Penn researchers to develop a novel switchable bispecific T cell engager that mitigates negative outcomes of immunotherapy.
Noor Momin harnesses the immune system to treat heart disease
A model of a heart

Image: Kjpargeter for Shutterstock

Noor Momin harnesses the immune system to treat heart disease

The Stephenson Foundation Term Assistant Professor of Innovation and her lab members work to engineer nanoparticles as medicinal vehicles to fit directly into a single cell.

From Penn Engineering Today